Journal Article

Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma

Yu, Weiping, Peng, Min, Cao, Huan, Li, Hui, Huang, Yamei, Gu, Jinyang, Shen, Chuanlai

2023

Overview

BackgroundTherapies for cholangiocarcinoma are largely limited and ineffective. Herein, we examined the role of the FGF and VEGF pathways in regulating lymphangiogenesis and PD-L1 expression in intrahepatic cholangiocarcinoma (iCCA).MethodsThe lymphangiogenic functions of FGF and VEGF were evaluated in lymphatic endothelial cells (LECs) and iCCA xenograft mouse models. The relationship between VEGF and hexokinase 2 (HK2) was validated in LECs by western blot, immunofluorescence, ChIP and luciferase reporter assays. The efficacy of the combination therapy was assessed in LECs and xenograft models. Microarray analysis was used to evaluate the pathological relationships of FGFR1 and VEGFR3 with HK2 in human lymphatic vessels.ResultsFGF promoted lymphangiogenesis through c-MYC-dependent modulation of HK2 expression. VEGFC also upregulated HK2 expression. Mechanistically, VEGFC phosphorylated components of the PI3K/Akt/mTOR axis to upregulate HIF-1α expression at the translational level, and HIF-1α then bound to the HK2 promoter region to activate its transcription. More importantly, dual FGFR and VEGFR inhibition with infigratinib and SAR131675 almost completely inhibited lymphangiogenesis, and significantly suppressed iCCA tumor growth and progression by reducing PD-L1 expression in LECs.ConclusionsDual FGFR and VEGFR inhibition inhibits lymphangiogenesis through suppression of c-MYC-dependent and HIF-1α-mediated HK2 expression, respectively. HK2 downregulation decreased glycolytic activity and further attenuated PD-L1 expression. Our findings suggest that dual FGFR and VEGFR blockade is an effective novel combination strategy to inhibit lymphangiogenesis and improve immunocompetence in iCCA.

• Publisher: Springer Nature B.V
• Subject: 1-Phosphatidylinositol 3-kinase / AKT protein / Animal models / c-Myc protein / Cholangiocarcinoma / Endothelial cells / Fibroblast growth factor receptor 1 / Fibroblast growth factor receptors / Glycolysis / Hexokinase / Hypoxia-inducible factor 1a / Immune evasion / Immunocompetence / Immunofluorescence / Lymphatic system / Myc protein / PD-L1 protein / TOR protein / Vascular endothelial growth factor / Vascular endothelial growth factor receptors / Xenografts